<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01074229</url>
  </required_header>
  <id_info>
    <org_study_id>STU00023440</org_study_id>
    <nct_id>NCT01074229</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane (TAP) Block Laparoscopic Hysterectomy</brief_title>
  <acronym>TAP HYS</acronym>
  <official_title>The Effect of Pre-operative Transversus Abdominis Plane (TAP) Block in the Quality of Recovery of Patients Undergoing Laparoscopic Hysterectomy: a Prospective, Randomized, Blinded Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The transversus abdominis plane (TAP) block involves the sensory nerve supply of the anterior
      -lateral abdominal wall where the T7-12 intercostal nerves, ilioinguinal, iliohypogastric and
      the lateral cutaneous branches of the dorsal rami of L1-3 are blocked with an injection of
      local anesthetic between the internal oblique abdominal muscle (IOAM) and the transverse
      abdominal muscle(TAM)This technique allows sensory blockade of the anterolateral abdominal
      wall via local anesthetic deposition superficial to the transversus abdominis muscle. It was
      first described by McDonnell et al. as a landmark technique to provide analgesia for lower
      abdominal surgery.

      Hebbart et al. subsequently described an ultrasound guided technique for the TAP block which
      they named posterior TAP block. The ultrasound allows identification of the external oblique
      abdominal muscles (EOAM),IOAM and TAM. Previous studies about ultrasound -guided regional
      anesthetic techniques suggest improved block quality and safety, which is primarily due to
      direct visualization of the relevant anatomy, the tip of the needle, and the spread of the
      local anesthetics.

      Clinical trials of the single shot posterior TAP block have shown a significant reduction in
      morphine consumption during the first 24-36 hours after surgery. More recently, El-dawlatly
      et al. demonstrated that ultrasound guided TAP block in patients undergoing laparoscopic
      cholecystectomy reduced perioperative opioid consumption by more than 50%.

      This is the first study to evaluate the effect of TAP block in the quality of recovery in
      patients undergoing laparoscopic hysterectomy and may help the pathway to make this an
      outpatient procedure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>QoR40 on the Day After Surgery</measure>
    <time_frame>1 day</time_frame>
    <description>QoR40 on the day after surgery. Quality of recovery is based on a score of 40-200. 40 being a poor recovery and 200 being a good recovery score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24 Total Morphine Consumption</measure>
    <time_frame>1 day</time_frame>
    <description>Total 24 total morphine consumption post operative.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>sterile normal saline as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug .5% Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Instillation of 20 cc of 0.5% ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 cc of 0.25% ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Instillation of 20 cc of 0.25% ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sterile normal saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug .5% Ropivacaine</intervention_name>
    <description>.5% ropivacaine 20 mls on each side of abdomen</description>
    <arm_group_label>Drug .5% Ropivacaine</arm_group_label>
    <other_name>.5% Ropivacaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 cc of 0.25% ropivacaine</intervention_name>
    <description>Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine</description>
    <arm_group_label>20 cc of 0.25% ropivacaine</arm_group_label>
    <other_name>.25% ropivacaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18-64 years

          -  Surgery: Laparoscopic Hysterectomy surgery

          -  ASA status: I and II

          -  Fluent in English

        Exclusion Criteria:

          -  History of allergy to local anesthetics

          -  History of chronic opioid use

          -  Pregnant patients

          -  BMI greater than 30

        Drop-out criteria:

          -  Patient or surgeon request

          -  Complications related to the procedure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio DeOliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jacobson GF, Shaber RE, Armstrong MA, Hung YY. Hysterectomy rates for benign indications. Obstet Gynecol. 2006 Jun;107(6):1278-83.</citation>
    <PMID>16738152</PMID>
  </reference>
  <reference>
    <citation>Babalola EO, Bharucha AE, Schleck CD, Gebhart JB, Zinsmeister AR, Melton LJ 3rd. Decreasing utilization of hysterectomy: a population-based study in Olmsted County, Minnesota, 1965-2002. Am J Obstet Gynecol. 2007 Mar;196(3):214.e1-7.</citation>
    <PMID>17346525</PMID>
  </reference>
  <reference>
    <citation>Lenz H, Sandvik L, Qvigstad E, Bjerkelund CE, Raeder J. A comparison of intravenous oxycodone and intravenous morphine in patient-controlled postoperative analgesia after laparoscopic hysterectomy. Anesth Analg. 2009 Oct;109(4):1279-83. doi: 10.1213/ane.0b013e3181b0f0bb.</citation>
    <PMID>19762758</PMID>
  </reference>
  <reference>
    <citation>Thiel JA, Kamencic H. Assessment of costs associated with outpatient total laparoscopic hysterectom. J Obstet Gynaecol Can. 2006 Sep;28(9):794-798. doi: 10.1016/S1701-2163(16)32258-7.</citation>
    <PMID>17022920</PMID>
  </reference>
  <reference>
    <citation>Lovatsis D, José JB, Tufman A, Drutz HP, Murphy K. Assessment of patient satisfaction with postoperative pain management after ambulatory gynaecologic laparoscopy. J Obstet Gynaecol Can. 2007 Aug;29(8):664-7.</citation>
    <PMID>17714620</PMID>
  </reference>
  <reference>
    <citation>Wills VL, Hunt DR. Pain after laparoscopic cholecystectomy. Br J Surg. 2000 Mar;87(3):273-84. Review.</citation>
    <PMID>10718794</PMID>
  </reference>
  <reference>
    <citation>Goldstein A, Grimault P, Henique A, Keller M, Fortin A, Darai E. Preventing postoperative pain by local anesthetic instillation after laparoscopic gynecologic surgery: a placebo-controlled comparison of bupivacaine and ropivacaine. Anesth Analg. 2000 Aug;91(2):403-7.</citation>
    <PMID>10910857</PMID>
  </reference>
  <reference>
    <citation>Shaw IC, Stevens J, Krishnamurthy S. The influence of intraperitoneal bupivacaine on pain following major laparoscopic gynaecological procedures. Anaesthesia. 2001 Nov;56(11):1041-4.</citation>
    <PMID>11703235</PMID>
  </reference>
  <reference>
    <citation>Møiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A qualitative systematic review of incisional local anaesthesia for postoperative pain relief after abdominal operations. Br J Anaesth. 1998 Sep;81(3):377-83.</citation>
    <PMID>9861124</PMID>
  </reference>
  <reference>
    <citation>Keita H, Benifla JL, Le Bouar V, Porcher R, Wachowska B, Bedairia K, Mantz J, Desmonts JM. Prophylactic ip injection of bupivacaine and/or morphine does not improve postoperative analgesia after laparoscopic gynecologic surgery. Can J Anaesth. 2003 Apr;50(4):362-7.</citation>
    <PMID>12670813</PMID>
  </reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2010</study_first_submitted>
  <study_first_submitted_qc>February 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2010</study_first_posted>
  <results_first_submitted>April 4, 2013</results_first_submitted>
  <results_first_submitted_qc>April 9, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 8, 2014</results_first_posted>
  <last_update_submitted>April 9, 2014</last_update_submitted>
  <last_update_submitted_qc>April 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Post Operative</keyword>
  <keyword>Opioids</keyword>
  <keyword>Laparoscopic</keyword>
  <keyword>Surgery</keyword>
  <keyword>Hysterectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Group B (control group) will receive sterile normal saline.</description>
        </group>
        <group group_id="P2">
          <title>20 cc of 0.5% Ropivacaine</title>
          <description>Group A (study group) 20 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="P3">
          <title>20 cc of 0.25% Ropivacaine</title>
          <description>Active Comparator 2. 20 cc of 0.25% ropivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Change to open surgical procedure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Group B (control group) will receive sterile normal saline.</description>
        </group>
        <group group_id="B2">
          <title>Study Drug</title>
          <description>Group A (study group) 20 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="B3">
          <title>20 cc of 0.25% Ropivacaine</title>
          <description>Active Comparator 2. 20 cc of 0.25% ropivacaine</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="9.6"/>
                    <measurement group_id="B2" value="45.4" spread="4.5"/>
                    <measurement group_id="B3" value="46.76" spread="6.4"/>
                    <measurement group_id="B4" value="46.55" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>QoR40 on the Day After Surgery</title>
        <description>QoR40 on the day after surgery. Quality of recovery is based on a score of 40-200. 40 being a poor recovery and 200 being a good recovery score.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PLACEBO</title>
            <description>Group B (control group) will receive sterile normal saline.</description>
          </group>
          <group group_id="O2">
            <title>20 cc of 0.5% Ropivacaine</title>
            <description>STUDY DRUG Group A (study group) 20 cc of 0.5% ropivacaine</description>
          </group>
          <group group_id="O3">
            <title>20 cc of 0.25% Ropivacaine</title>
            <description>Active Comparator 2. 20 cc of 0.25% ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>QoR40 on the Day After Surgery</title>
          <description>QoR40 on the day after surgery. Quality of recovery is based on a score of 40-200. 40 being a poor recovery and 200 being a good recovery score.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152" spread="22.8" lower_limit="136" upper_limit="167"/>
                    <measurement group_id="O2" value="180" spread="12.16" lower_limit="169" upper_limit="190"/>
                    <measurement group_id="O3" value="180" spread="15.3" lower_limit="161" upper_limit="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>Using Dunns test with Bonferroni conrrection for individual comparisons.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Dunns test</method>
            <method_desc>Bonferonni correction</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9</ci_lower_limit>
            <ci_upper_limit>37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Dunns Test</method>
            <method_desc>Bonferroni correction</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14</ci_lower_limit>
            <ci_upper_limit>42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24 Total Morphine Consumption</title>
        <description>Total 24 total morphine consumption post operative.</description>
        <time_frame>1 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Group B (control group) will receive sterile normal saline.</description>
          </group>
          <group group_id="O2">
            <title>20 cc of 0.5% Ropivacaine</title>
            <description>Group A (study group) 20 cc of 0.5% ropivacaine</description>
          </group>
          <group group_id="O3">
            <title>20 cc of 0.25% Ropivacaine</title>
            <description>Active Comparator 2. 20 cc of 0.25% ropivacaine</description>
          </group>
        </group_list>
        <measure>
          <title>24 Total Morphine Consumption</title>
          <description>Total 24 total morphine consumption post operative.</description>
          <units>miligrams of morphine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.75" spread="10.75"/>
                    <measurement group_id="O2" value="12.5" spread="9.84"/>
                    <measurement group_id="O3" value="17.5" spread="13.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.05</p_value>
            <method>Kruskal-Wallis</method>
            <method_desc>With Dunns test and Bonferonni correction.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>Dunns test</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3</ci_lower_limit>
            <ci_upper_limit>15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <method>Dunns test</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1</ci_lower_limit>
            <ci_upper_limit>12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Group B (control group) will receive sterile normal saline.</description>
        </group>
        <group group_id="E2">
          <title>Study Drug</title>
          <description>Group A (study group) 20 cc of 0.5% ropivacaine</description>
        </group>
        <group group_id="E3">
          <title>20 cc of 0.25% Ropivacaine</title>
          <description>Active Comparator 2. 20 cc of 0.25% ropivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Ropivacaine blood levels were not obtained. Distribution of study drug unable to gauge due to general anesthesia. Study underpowered to detect a difference in opioid consumption or global QoR-40 between the ropivacaine 0.25% and 0.5% groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-926-8373</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

